MX368228B - Anticuerpos que se unen específicamente a her2. - Google Patents

Anticuerpos que se unen específicamente a her2.

Info

Publication number
MX368228B
MX368228B MX2015015110A MX2015015110A MX368228B MX 368228 B MX368228 B MX 368228B MX 2015015110 A MX2015015110 A MX 2015015110A MX 2015015110 A MX2015015110 A MX 2015015110A MX 368228 B MX368228 B MX 368228B
Authority
MX
Mexico
Prior art keywords
antibody
her2
present
cancer
trastuzumab
Prior art date
Application number
MX2015015110A
Other languages
English (en)
Other versions
MX2015015110A (es
Inventor
Lee Jong-Seo
Kim Kyu-Tae
Lee Young-Ha
LEE Sook-Yeon
Hwang In-Sik
KO Bong-Kook
Original Assignee
Abclon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abclon Inc filed Critical Abclon Inc
Publication of MX2015015110A publication Critical patent/MX2015015110A/es
Publication of MX368228B publication Critical patent/MX368228B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo HER2 novedoso para su administración simultánea, que se utiliza para prevenir o tratar cáncer. El anticuerpo de la presente invención se une específicamente a HER2, el cual se sobre-expresa en células de cáncer (particularmente, en células de cáncer de mama y cáncer gástrico), y se une a un epítopo diferente de aquel al cual se une trastuzumab. El anticuerpo de la presente invención tiene una secuencia única debido a una homología muy baja comparada con la secuencia CDR de los anticuerpos dirigidos a HER2 conocidos. El anticuerpo de la presente invención extermina células de cáncer con una capacidad notablemente mejorada para exterminar células de cáncer cuando se administra simultáneamente con trastuzumab y de este modo, es muy útil para prevenir o tratar cáncer (particularmente cáncer de mama o cáncer gástrico). La eficacia notable de la administración simultánea del anticuerpo de la presente invención se considera, sin desear limitarse por la teoría que se debe a que el anticuerpo de la presente invención se une a un epítopo de HER2 diferente al que se une trastuzumab, inhibiendo por lo tanto HER2 de forma cooperativa con trastuzumab.
MX2015015110A 2013-05-16 2014-05-14 Anticuerpos que se unen específicamente a her2. MX368228B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130055912 2013-05-16
PCT/KR2014/004317 WO2014185704A1 (ko) 2013-05-16 2014-05-14 Her2에 특이적으로 결합하는 항체

Publications (2)

Publication Number Publication Date
MX2015015110A MX2015015110A (es) 2016-08-11
MX368228B true MX368228B (es) 2019-09-24

Family

ID=51898619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015110A MX368228B (es) 2013-05-16 2014-05-14 Anticuerpos que se unen específicamente a her2.

Country Status (12)

Country Link
US (1) US10174116B2 (es)
EP (1) EP2998319B1 (es)
JP (2) JP6234548B2 (es)
KR (1) KR101453462B1 (es)
CN (1) CN105164160B (es)
AU (1) AU2014266118B2 (es)
BR (1) BR112015027400B1 (es)
CA (1) CA2910407C (es)
ES (1) ES2710707T3 (es)
MX (1) MX368228B (es)
RU (1) RU2628094C2 (es)
WO (1) WO2014185704A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104118168A (zh) * 2010-02-10 2014-10-29 宇部兴产株式会社 聚酰亚胺膜、含它的聚酰亚胺层压体和含它的聚酰亚胺金属层压体
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
KR101796277B1 (ko) * 2016-04-12 2017-11-13 앱클론(주) 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체
EP3241847A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2 binding antibodies
EP3455260B1 (en) * 2016-05-12 2022-07-06 Agency for Science, Technology and Research Anti-erbb-2 antibodies and uses thereof
CN110121505B (zh) 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 嵌合抗原受体和表达其的自然杀伤细胞
CN110709419B (zh) * 2017-01-06 2023-11-28 博奥信生物技术（南京）有限公司 Erbb2抗体及其用途
SG11201907753TA (en) * 2017-02-24 2019-09-27 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
AU2018370195B2 (en) * 2017-11-14 2022-01-13 Green Cross Lab Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN110790840A (zh) * 2018-08-01 2020-02-14 三生国健药业（上海）股份有限公司 结合人her2的抗体、其制备方法和用途
KR20200098831A (ko) 2019-02-13 2020-08-21 건국대학교 글로컬산학협력단 신규한 부위-특이적 항체 절편 플랫폼
JP7727549B2 (ja) * 2019-03-22 2025-08-21 セルティス・セラピューティクス・ピーティーワイ・リミテッド 抗ｈｅｒ２結合分子
EP3962525A1 (en) * 2019-05-02 2022-03-09 MAB Discovery GmbH Combination of her2 antibodies
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途
CN119431564B (zh) * 2025-01-10 2025-04-11 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体或其抗原结合片段、hpv16检测产品及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
WO1988007085A1 (en) 1987-03-20 1988-09-22 Creative Biomolecules, Inc. Process for the purification of recombinant polypeptides
AU601273B2 (en) 1987-03-20 1990-09-06 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
CA2269204C (en) * 1996-10-18 2012-01-24 Genentech, Inc. Anti-erbb2 antibodies
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
BRPI0416190A (pt) 2003-11-06 2007-01-23 Pfizer Prod Inc combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
WO2005113001A1 (en) 2004-05-20 2005-12-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
AU2005271523B2 (en) 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
WO2008019290A2 (en) * 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to erbb 2
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
ES2407957T3 (es) 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
EP2448599A1 (en) 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
JP6177231B2 (ja) * 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体

Also Published As

Publication number Publication date
RU2628094C2 (ru) 2017-08-14
KR101453462B1 (ko) 2014-10-23
RU2015146664A (ru) 2017-06-21
HK1217500A1 (zh) 2017-01-13
CA2910407C (en) 2018-12-11
JP6234548B2 (ja) 2017-11-22
WO2014185704A1 (ko) 2014-11-20
EP2998319B1 (en) 2018-11-28
CA2910407A1 (en) 2014-11-20
AU2014266118A1 (en) 2015-11-12
BR112015027400B1 (pt) 2023-04-25
EP2998319A4 (en) 2017-01-25
MX2015015110A (es) 2016-08-11
EP2998319A1 (en) 2016-03-23
US20160053011A1 (en) 2016-02-25
CN105164160A (zh) 2015-12-16
BR112015027400A2 (pt) 2017-08-29
JP2016518368A (ja) 2016-06-23
JP2018008954A (ja) 2018-01-18
US10174116B2 (en) 2019-01-08
JP6487968B2 (ja) 2019-03-20
AU2014266118B2 (en) 2017-03-30
ES2710707T3 (es) 2019-04-26
CN105164160B (zh) 2018-11-30

Similar Documents

Publication Publication Date Title
MX2015015110A (es) Anticuerpos que se unen especificamente a her2.
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
MX2014001374A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MY202516A (en) Antibodies to tigit
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
PH12016501672A1 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
MX2014001373A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
MX2022002504A (es) Anticuerpos para cd40.
EA202090204A1 (ru) Анти-cd137 антитела
TN2016000142A1 (en) Specific anti-cd38 antibodies for treating human cancers.
JOP20200312A1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
NZ710929A (en) Antibody drug conjugates
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2018014560A (es) Metodos para el tratamiento de la miastenia gravis generalizada refractaria.
MX2020002406A (es) Anticuerpo anti-epha4.
NZ630864A (en) Use of semaphorin-4d binding molecules to promote neurogenesis following stroke
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
NZ625758A (en) Method for treating breast cancer
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
HK1198135A1 (en) Prevention and treatment of pain using antibodies to lysophosphatidic acid
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2016010852A (es) Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso.

Legal Events

Date Code Title Description
FG Grant or registration